Bio_Spectrum_July_2017

(^18) SUPPLIER NEWS l BioSpectrum | July 2017 | http://www.biospectrumindia.com
Thermo Fisher Scientific Inc., the world leader in
serving science, and Patheon N.V. a leading global
provider of high-quality drug development and delivery
solutions to the pharmaceutical and biopharma
sectors, announced that their boards of directors have
approved Thermo Fisher’s acquisition of Patheon.
Thermo Fisher will commence a tender offer to acquire
all of the issued and outstanding shares of Patheon for
$35.00 per share in cash. The transaction represents
a purchase price of approximately $7.2 billion, which
includes the assumption of approximately $2.0 billion
of net debt.
Patheon provides comprehensive, integrated and
highly customizable solutions as well as the expertise
to help biopharmaceutical companies of all sizes satisfy
complex development and manufacturing needs. It
is a leader in the high-growth, $40 billion Contract
Development and Manufacturing Organization
(CDMO) market, which is fueled by growing customer
demand for end-to-end solutions, flexible and scalable
capacity, and regulatory expertise.
Patheon has an extensive network of state-of-
the-art facilities primarily in North America and
Europe, and approximately 9,000 professionals
worldwide. The company generated 2016 revenue of
approximately $1.9 billion and will become part of
Thermo Fisher’s Laboratory Products and Services
Segment.
This acquisition will significantly strengthen
Thermo Fisher’s unique value proposition for
pharmaceutical and biotech customers by adding
highly complementary services. The combined
company’s extensive and deep relationships in the
biopharma industry will enable significant cross-
selling opportunities.
The transaction is expected to be immediately
and significantly accretive to Thermo Fisher’s
adjusted EPS by $0.30 in the first full year after close.
Thermo Fisher expects to realize total synergies of
approximately $120 million by year three following
the close, consisting of approximately $90 million
of cost synergies and approximately $30 million of
adjusted operating income benefit from revenue-
related synergies.
Agilent Technologies Inc.
and Agendia, Inc. have jointly
announced an agreement
to expand their relationship
to include the development
of an RNASeq kit version
of Agendia’s currently
marketed MammaPrint and
BluePrint tests.
Agendia’s MammaPrint
test provides High-Risk
or Low-Risk test results to
assess the risk of distant metastasis
within five years, in breast cancer
patients with Stage I or Stage
II disease. Agendia’s BluePrint
test builds on the foundational
prognostic precision of
MammaPrint, to classify the breast
cancer into one of four molecular
subtypes. These results help to
predict clinical outcomes in women
with early-stage breast cancer.
Using Agilent’s SureSelect
target enrichment system, the new
RNAseq kit will enable Agendia
to develop and perform the
MammaPrint and BluePrint tests,
as next-generation sequencing
assays. This capability will allow
the tests to be run in decentralized
settings that can utilize a larger
footprint of next-generation
sequencing instruments, thus
affording patients global access
to these revolutionary tests. The
ability to perform these tests at
locations closer to the patients,
provides greater accessibility and
the potential for more cancer
patients to get better
individualized treatment
management. The initial
phase of kit development is
expected to be completed
in 2017, providing early
access to limited markets in
Europe.
Agilent Technologies
is a leading provider of
target enrichment for next-
generation DNA and RNA
sequencing solutions. Target
enrichment saves researchers time
and resources by enabling them to
focus on regions of interest rather
than looking at the entire genome.
Agendia is a leading molecular
diagnostics company that develops
and markets FFPE-based genomic
diagnostic products. Agendia’s
MammaPrint microarray-based
diagnostic test is currently the
only FDA-cleared breast cancer
recurrence test intended for use in
breast cancer patients of all ages.
Agilent in agreement with Agendia for cancer diagnostics
Thermo Fisher Scientific acquires Patheon